NCT07593625招募中不适用
Evaluation Glucose Control Using a Next-Generation Automated Insulin Delivery Algorithm in Individuals With Type 1 Diabetes: EVOLUTION T1D
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Percentage of time <54 mg/dL
研究概览
简要总结
Feasibility study to evaluate the safety and feasibility of Omnipod automated insulin delivery algorithms in individuals with type 1 diabetes. This study will enroll up to 80 participants to have a minimum of 48 participants to initiate the use of Omnipod. The study will include hotel and outpatient evaluation periods.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age at time of consent 2-70 years (inclusive)
- •Type 1 diabetes diagnosis for at least 6 months, for those aged 8-70 years, or 3 months for those aged 2-7 years, based on Investigator assessment
- •Basal/Bolus insulin delivery via multiple daily injections or insulin pump with or without automation
- •Willing to use the following types of U-100 insulin during the study: Humalog U-100, Novorapid or their generic equivalents
- •Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
- •If using noninsulin glucose-lowering medications or weight reduction medications, dose has been stable for 6-weeks prior to screening; and participant is willing to not change the dose unless required for safety purposes.
- •Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol
- •Willing to wear the system continuously throughout the study
- •Willing and able to sign the Informed Consent Form (ICF) or has a parent/guardian willing and able to sign the ICF. Assent will be obtained from participants per local regulatory requirements
- •Able to read and understand English
- •If of childbearing potential, willing and able to have pregnancy testing
排除标准
- •Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse.
- •Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or a history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or arrhythmias requiring intervention within the 12 months prior to screening
- •Any planned surgery during the study which could be considered major in the opinion of the Investigator
- •History of more than 1 severe hypoglycaemia in the past 6 months. Severe hypoglycaemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions
- •History of more than 1 diabetic ketoacidosis (DKA) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
- •Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c
- •Use of hydroxyurea
- •Plans to receive blood transfusion over the course of the study
- •Has taken systemic corticosteroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to screening or plans to take oral or injectable steroids during the study
- •Use of non-insulin glucose-lowering medication or weight loss medications other than metformin and/or GLP1, in the 4 weeks prior to screening. Participants taking metformin and/or GLP1 should remain on a steady dose without dose increases during study participation
- •Pregnant or lactating, or is of childbearing potential and not using an acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilisation such as tubal ligation or hysterectomy, or vasectomised partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal).
- •In the past 30-days, has participated in a clinical study using any investigational drug or any investigational device that in the opinion of the investigator may have therapeutic impact on their diabetes management. Additionally, may not intend to participate in any other interventional clinical study during this study period
- •Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment
- •Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned
研究组 & 干预措施
Adults and pediatrics with T1D using Omnipod S
Experimental
干预措施: Omnipod S (Device)
Adults with T1D using Omnipod M
Experimental
干预措施: Omnipod M System (Device)
结局指标
主要结局
Percentage of time <54 mg/dL
时间窗: 72-hour Omnipod M Hotel Period
CGM percent time \<54 mg/dL compared to standard therapy
Percentage of time <70 mg/dL
时间窗: 72-hour Omnipod M Hotel Period
CGM percent time \<70 mg/dL compared to standard therapy
Percentage of time >180 mg/dL
时间窗: 72-hour Omnipod M Hotel Period
CGM percent time \>180 mg/dL compared to standard therapy
Percentage of time <54 mg/dL
时间窗: 4-week Omnipod M outpatient
CGM percent time \<54 mg/dL compared to standard therapy
Percentage of time <54 mg/dL
时间窗: Final 3 weeks of Omnipod S outpatient
CGM percent time \<54 mg/dL compared to initial data collection phase
Percentage of time <70 mg/dL
时间窗: 4-week Omnipod M outpatient
CGM percent time \<70 mg/dL compared to standard therapy
Percentage of time <70 mg/dL
时间窗: Final 3-weeks Omnipod S outpatient
CGM percent time \<70 mg/dL compared to initial data collection phase
Percentage of time >180 mg/dL
时间窗: 4-week Omnipod M outpatient
CGM percent time \>180 mg/dL compared to standard therapy
Percentage of time >180 mg/dL
时间窗: Final 3-weeks Omnipod S outpatient
CGM percent time \>180 mg/dL compared to initial data collection phase
次要结局
- Post-prandial glycemic metrics(Up to 4-hours following tracked meal)
- Post-exercise session glycemic metrics(Up to 2-hours following exercise)
- Mean glucose(4-weeks Omnipod M outpatient)
- Mean glucose(Final 3-weeks Omnipod S outpatient)
- Percentage of time >250 mg/dL(4-weeks Omnipod M outpatient)
- Percentage of time >250 mg/dL(Final 3-weeks Omnipod S outpatient)
- Percentage of time >300 mg/dL(4-weeks Omnipod M outpatient)
- Percentage of time >300 mg/dL(Final 3-weeks Omnipod S outpatient)
- Percentage of time 70-180 mg/dL(4-weeks Omnipod M outpatient)
- Percentage of time 70-180 mg/dL(Final 3-weeks Omnipod S outpatient)
- Standard Deviation(4-weeks Omnipod M outpatient)
- Standard Deviation(Final 3-weeks Omnipod S outpatient)
- Coefficient of variation(4-weeks Omnipod M outpatient)
- Coefficient of variation(Final 3-weeks Omnipod S outpatient)
- Average total daily insulin (TDI)(4-weeks Omnipod M outpatient)
- Average total daily insulin (TDI)(Final 3-weeks Omnipod S outpatient)
- Average TDI/kg(4-weeks Omnipod M outpatient)
- Average TDI/kg(Final 3-weeks Omnipod S outpatient)
- Incidence rate of severe hypoglycemia (SH)(Final 3-weeks Omnipod S outpatient)
- Incidence rate of diabetic ketoacidosis (DKA)(Final 3-weeks Omnipod S outpatient)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
An Evaluation of the Omnipod® M System in Adults With Type 2 DiabetesType 2 Diabetes MellitusNCT07276776Insulet Corporation40
招募中
不适用
Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)Type 1 DiabetesDiabetesDiabetes MellitusNCT07317102Insulet Corporation152
Unknown
不适用
评价持续葡萄糖监测系统用于成人糖尿病患者的有效性和安全性的前瞻性、多中心、自身对照临床试验ChiCTR2400085481上海微创生命科技有限公司
招募中
不适用
Feasibility Testing of the "MyGlucoCare" Smartphone App for Women With Gestational DiabetesNCT07372872Hong Kong Metropolitan University30
尚未招募
不适用
CGM in Acute Ischemic StrokeHyperglycemiaAcute Ischemic StrokeDiabetes (DM)Diabetes Type 2StrokeNCT07510919Isala82